One of China’s leading drugmakers has asked the Shanghai stock exchange to suspend trading of its shares from Monday after securities regulators confirmed the company faked its financial statements between 2016 and 2018.
The Shanghai-listed Kangmei Pharmaceutical Co. Ltd was found to have used fake bank deposit slips to inflate its cash holding, forged documents for non-existent business activities and transferred its funds to affiliates to trade its own stocks, said the China Securities Regulatory Commission (CSRC . . .
To continue reading, please subscribe. You will get
- Original and in-depth reporting with details, data and perspectives you don't read elsewhere
- THE WIRE - a real-time financial news platform focused on China
- Daily Brief newsletter to get you prepared for every trading day
- An indispensable and reliable source of information on China's economy and financial markets
We highly value independence. We are solely funded by subscriptions from thousands of readers like you. Not ready for our full service? Try Free Weekly Newsletter first.
Already have an account? Sign In